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Abnormal vascular smooth muscle cell (VSMC) prolifera-
tion contributes to neointima formation during the
pathogenesis of atherosclerosis and restenosis. Drugs
interfering with the cell cycle progression of VSMCs are
therefore promising candidates for the treatment of vascu-
loproliferative diseases. Roscovitine (ROSC) has been
characterised as a selective CDK1/2/5/7/9 inhibitor using
enzyme-based assays, but the inhibition of other kinases
(e.g. ERK, AuroraA) has been demonstrated as well. It has
been shown that ROSC inhibits VSMC growth but the
mode of action has not been solved satisfyingly and there
are no data describing its influence on platelet-derived
growth factor (PDGF) signalling, a major proliferative
stimulus for VSMCs. We therefore investigated the effect
of ROSC on PDGF-activated VSMCs. Using a BrdU
incooporation assay, we show that ROSC inhibits PDGF-
induced VSMC growth in a concentration dependent
manner (IC50: ~15 μM). Detailed FACS analysis of the cell
cycle revealed that ROSC delays S-phase entry upon PDGF
stimulation without leading to enhanced apoptosis. By
Western blot analysis we excluded that ROSC has any
inhibitory effect on common early signaling events (phos-
phorylation of ERK, p38, Akt). Contrary to results pub-
lished on colon carcinoma cells, where ROSC causes a loss
of cyclinD1, we demonstrate that cyclinD1 levels are
markedly increased even after 24 h of PDGF stimulation,
confirming that there is no interference with early steps in
cell cycle progression. Despite high levels of cyclinD1 the
phosphorylation of the retinoblastoma protein at Ser807/
811 is delayed and reduced, as is the induction of the early
S-phase cyclin A. We conclude that ROSC limits VSMC
growth by directly inhibiting CDK2 or 4 and constitutes a
promising compound for further development as e.g.
stent-coating agent.
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